Compare ZUMZ & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZUMZ | TRDA |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 386.8M |
| IPO Year | 2005 | 2021 |
| Metric | ZUMZ | TRDA |
|---|---|---|
| Price | $26.22 | $9.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $18.00 | ★ $24.50 |
| AVG Volume (30 Days) | 175.5K | ★ 298.3K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $900,253,000.00 | $61,520,000.00 |
| Revenue This Year | $5.50 | N/A |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | $809.88 | ★ N/A |
| Revenue Growth | ★ 1.64 | N/A |
| 52 Week Low | $11.31 | $4.93 |
| 52 Week High | $26.76 | $21.79 |
| Indicator | ZUMZ | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 74.75 | 69.98 |
| Support Level | $25.35 | $8.17 |
| Resistance Level | $26.76 | $10.75 |
| Average True Range (ATR) | 1.00 | 0.67 |
| MACD | 0.36 | 0.07 |
| Stochastic Oscillator | 89.78 | 73.52 |
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.